Literature DB >> 16168278

Aspirin administered at bedtime, but not on awakening, has an effect on ambulatory blood pressure in hypertensive patients.

Ramón C Hermida1, Diana E Ayala, Carlos Calvo, José E López.   

Abstract

OBJECTIVES: The purpose of this research was to investigate in untreated hypertensive patients the effects on ambulatory blood pressure (BP) of aspirin (ASA) administered at different times of the day.
BACKGROUND: Previous studies have shown that ASA produces an administration time-dependent inhibition of angiotensin II. Low-dose ASA has also been shown to reduce BP when administered before bedtime, as opposed to upon awakening, in normotensive and hypertensive volunteers, and in pregnant women at high risk for preeclampsia.
METHODS: We studied 328 untreated patients with grade 1 hypertension, 44.0 +/- 12.6 years of age, randomly divided into three groups: nonpharmacological hygienic-dietary recommendations, the same recommendations and ASA (100 mg/day) on awakening, or the same recommendations and ASA before bedtime. Blood pressure was measured every 20 min during the day and every 30 min at night for 48 consecutive h before and after 3 months of intervention.
RESULTS: After three months of nonpharmacological intervention, there was a small and nonsignificant reduction of BP (<0.2 mm Hg; p = 0.648). Blood pressure was slightly elevated after aspirin on awakening (2.6/1.6 mm Hg in the 24-h mean of systolic/diastolic BP; p = 0.002). A significant BP reduction, however, was observed in the patients who received aspirin before bedtime (6.8/4.6 mm Hg in systolic/diastolic BP; p < 0.001).
CONCLUSIONS: This prospective trial documents a significant administration time-dependent effect of low-dose ASA on BP in untreated hypertensive patients. The timed administration of low-dose ASA could provide a valuable approach, beyond the secondary prevention of cardiovascular disease, in the added BP control of patients with mild essential hypertension.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16168278     DOI: 10.1016/j.jacc.2004.08.071

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  29 in total

Review 1.  Antihypertensive effects of aspirin: what is the evidence?

Authors:  Leonelo E Bautista; Lina M Vera
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

2.  Time-Dependent Hypotensive Effect of Aspirin in Mice.

Authors:  Lihong Chen; Guangrui Yang; Jiayang Zhang; Baoyin Ren; Soonyew Tang; Xuanwen Li; Garret A FitzGerald
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-12       Impact factor: 8.311

Review 3.  Role of the circadian system in cardiovascular disease.

Authors:  Saurabh S Thosar; Matthew P Butler; Steven A Shea
Journal:  J Clin Invest       Date:  2018-06-01       Impact factor: 14.808

Review 4.  Chronotherapy for Hypertension.

Authors:  N P Bowles; S S Thosar; M X Herzig; S A Shea
Journal:  Curr Hypertens Rep       Date:  2018-09-28       Impact factor: 5.369

5.  Aspirin in the prevention of preeclampsia: the conundrum of how, who and when.

Authors:  Renuka Shanmugalingam; Annemarie Hennessy; Angela Makris
Journal:  J Hum Hypertens       Date:  2018-09-19       Impact factor: 3.012

6.  Can resistance to aspirin be reversed after an additional dose?

Authors:  David Vivas; Esther Bernardo; Juan Carlos García-Rubira; Luis Azcona; Ivan Núñez-Gil; Juan Jose González-Ferrer; Carlos Macaya; Dominick J Angiolillo; Antonio Fernández-Ortiz
Journal:  J Thromb Thrombolysis       Date:  2011-10       Impact factor: 2.300

7.  Regulation on RhoA in vascular smooth muscle cells under inflammatory stimulation proposes a novel mechanism mediating the multiple-beneficial action of acetylsalicylic acid.

Authors:  Dong-Bo Li; Guo-Jie Yang; Hong-Wei Xu; Zhi-Xuan Fu; Shan-Wei Wang; Shen-Jiang Hu
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

8.  Histone deacetylase 3 antagonizes aspirin-stimulated endothelial nitric oxide production by reversing aspirin-induced lysine acetylation of endothelial nitric oxide synthase.

Authors:  Saet-Byel Jung; Cuk-Seong Kim; Asma Naqvi; Tohru Yamamori; Ilwola Mattagajasingh; Timothy A Hoffman; Marsha P Cole; Ajay Kumar; Jeremy S Dericco; Byeong-Hwa Jeon; Kaikobad Irani
Journal:  Circ Res       Date:  2010-08-12       Impact factor: 17.367

9.  Salicylates dilate blood vessels through inhibiting PYK2-mediated RhoA/Rho-kinase activation.

Authors:  Zhekang Ying; Fernanda R C Giachini; Rita C Tostes; Robert Clinton Webb
Journal:  Cardiovasc Res       Date:  2009-03-10       Impact factor: 10.787

Review 10.  Factors affecting the development of adverse drug reactions (Review article).

Authors:  Muaed Jamal Alomar
Journal:  Saudi Pharm J       Date:  2013-02-24       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.